# Study To Evaluate The Pharmacokinetic, Safety And Tolerability Of Single Or Multiple Subcutaneous Doses of Recifercept

> **NCT04543344** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Recifercept
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04543344
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-17
- **Primary completion:** 2021-08-03
- **Final completion:** 2021-11-26
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04543344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04543344, "Study To Evaluate The Pharmacokinetic, Safety And Tolerability Of Single Or Multiple Subcutaneous Doses of Recifercept". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04543344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*